Business Group on Health · 2026-04-13 · 32 min
Liquid biopsy tests, blood tests with the potential to detect up to 50 types of cancers, are being embraced by some in the health care community but viewed with careful consideration by others. In this episode, Jason Oke , medical statistician and lecturer at the University of Oxford’s Centre for Evidence-based Medicine, discusses the promise of these multi-cancer, early detection tests, alongside their limitations when it comes to real world application. He explains how effective screening tests of all kinds are measured, shares data from randomized trials that early detection tests show, and reveals how sensitivity, specificity, over-diagnosis and “healthy screenee bias” contribute to test value. Employees are excited about the potential of these tests. Employers should listen in for an unbiased, data-backed perspective to determine if benefits programs should evolve to include this offering. Guest: Jason Oke | Medical statistician and lecturer in medical statistics and cancer research at the University of Oxford
Psychological Strength and Well-being: The Key to Peak Performance62 / 100Decoding the Science of Chronic PainBeyond Burnout: Supporting the Emerging Mental Health Challenges Facing Millennials and Gen ZSimple Screening; Big Impact: Kidney Care Around the GlobeThe Reality of Today’s Aging Workforce and the Longevity Landscape